We are developing SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.
Reason to Believe in Target
Human Genetics Support
|Epidemiology~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
|Disease Hemophilia A, B|